The Investor
26 Aug 2026, 16:18
Abbott Wins FDA Authorization for World’s First Dual Glucose-Ketone Sensor
Abbott Laboratories (NYSE: ABT) has received U.S. Food and Drug Administration authorization for Libre Duo 10 Day, which the company says is the world’s first wearable system capable of continuously monitoring both glucose and ketone levels.
The authorization represents an important expansion of Abbott’s diabetes-care technology beyond conventional continuous glucose monitoring. The company plans to launch Libre Duo 10 Day in the United States later in 2026.
Libre Duo Targets a Critical Diabetes Risk
Libre Duo continuously tracks glucose while monitoring ketone levels in the background. Rising ketones can signal the development of diabetic ketoacidosis, or DKA, a potentially life-threatening complication that can progress rapidly when the body does not have enough insulin.
Traditional blood or urine ketone tests provide a single reading and generally require users to recognize when testing is necessary. Abbott’s system instead continuously monitors ketones and is designed to alert users when levels are rising.
The device received FDA De Novo authorization after previously receiving Breakthrough Device designation. According to Abbott, Libre Duo is the first system to meet both the FDA’s integrated continuous glucose monitoring standard and its new integrated continuous glucose and ketone monitoring standard.
The technology is intended for people with diabetes aged two years and older and offers up to 10 days of wear.
Integration With Insulin Delivery Systems Expands Opportunity
A potentially important commercial component is Abbott’s plan to integrate Libre Duo with automated insulin delivery systems.
Abbott expects compatibility with Beta Bionics’ iLet and Sequel Med Tech’s twiist systems by the end of 2026, followed by integrations with Insulet and Tandem devices in 2027. Abbott is also collaborating with MiniMed on an exclusive integration between Abbott-manufactured dual glucose-ketone sensors and MiniMed smart-dosing systems, expected in 2027.
Libre Duo will also connect with Abbott’s broader Libre ecosystem, including LibreView for healthcare providers and LibreLinkUp for caregivers.
Why the FDA Authorization Matters for Abbott
The approval strengthens Abbott’s competitive position in the rapidly developing continuous glucose monitoring market by introducing a capability beyond glucose measurement alone.
Rather than competing only on CGM accuracy, sensor size, wear duration and software features, Abbott is adding continuous ketone monitoring as a new layer of clinical functionality. The technology could be particularly relevant for insulin users and people taking SGLT2 medications who may face increased risk from elevated ketones.
The authorization also expands Abbott’s opportunity to make its Libre platform more deeply integrated into automated diabetes-management systems. If dual glucose-ketone sensing becomes incorporated into insulin pumps and smart-dosing platforms, Libre Duo could strengthen Abbott’s position within the broader diabetes-device ecosystem rather than functioning solely as a standalone sensor.
Abbott had already secured CE Mark approval for Libre Duo systems earlier in 2026. The FDA authorization now clears the way for the technology to enter the important U.S. market later this year.
Abbott Laboratories (NYSE: ABT) has received U.S. Food and Drug Administration authorization for Libre Duo 10 Day, which the company says is the world’s first wearable system capable of continuously monitoring both glucose and ketone levels.
The authorization represents an important expansion of Abbott’s diabetes-care technology beyond conventional continuous glucose monitoring. The company plans to launch Libre Duo 10 Day in the United States later in 2026.
Libre Duo Targets a Critical Diabetes Risk
Libre Duo continuously tracks glucose while monitoring ketone levels in the background. Rising ketones can signal the development of diabetic ketoacidosis, or DKA, a potentially life-threatening complication that can progress rapidly when the body does not have enough insulin.
Traditional blood or urine ketone tests provide a single reading and generally require users to recognize when testing is necessary. Abbott’s system instead continuously monitors ketones and is designed to alert users when levels are rising.
The device received FDA De Novo authorization after previously receiving Breakthrough Device designation. According to Abbott, Libre Duo is the first system to meet both the FDA’s integrated continuous glucose monitoring standard and its new integrated continuous glucose and ketone monitoring standard.
The technology is intended for people with diabetes aged two years and older and offers up to 10 days of wear.
Integration With Insulin Delivery Systems Expands Opportunity
A potentially important commercial component is Abbott’s plan to integrate Libre Duo with automated insulin delivery systems.
Abbott expects compatibility with Beta Bionics’ iLet and Sequel Med Tech’s twiist systems by the end of 2026, followed by integrations with Insulet and Tandem devices in 2027. Abbott is also collaborating with MiniMed on an exclusive integration between Abbott-manufactured dual glucose-ketone sensors and MiniMed smart-dosing systems, expected in 2027.
Libre Duo will also connect with Abbott’s broader Libre ecosystem, including LibreView for healthcare providers and LibreLinkUp for caregivers.
Why the FDA Authorization Matters for Abbott
The approval strengthens Abbott’s competitive position in the rapidly developing continuous glucose monitoring market by introducing a capability beyond glucose measurement alone.
Rather than competing only on CGM accuracy, sensor size, wear duration and software features, Abbott is adding continuous ketone monitoring as a new layer of clinical functionality. The technology could be particularly relevant for insulin users and people taking SGLT2 medications who may face increased risk from elevated ketones.
The authorization also expands Abbott’s opportunity to make its Libre platform more deeply integrated into automated diabetes-management systems. If dual glucose-ketone sensing becomes incorporated into insulin pumps and smart-dosing platforms, Libre Duo could strengthen Abbott’s position within the broader diabetes-device ecosystem rather than functioning solely as a standalone sensor.
Abbott had already secured CE Mark approval for Libre Duo systems earlier in 2026. The FDA authorization now clears the way for the technology to enter the important U.S. market later this year.
